HYL Stock Overview
Engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.24 |
| 52 Week High | €14.10 |
| 52 Week Low | €2.89 |
| Beta | 0.56 |
| 11 Month Change | -55.21% |
| 3 Month Change | -55.21% |
| 1 Year Change | -54.24% |
| 33 Year Change | -62.57% |
| 5 Year Change | n/a |
| Change since IPO | -49.57% |
Recent News & Updates
Shareholder Returns
| HYL | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | -55.2% | 0.1% | -0.8% |
| 1Y | -54.2% | 21.1% | 3.5% |
Return vs Industry: HYL underperformed the Belgian Pharmaceuticals industry which returned 21.1% over the past year.
Return vs Market: HYL underperformed the Belgian Market which returned 3.5% over the past year.
Price Volatility
| HYL volatility | |
|---|---|
| HYL Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 6.6% |
| 10% least volatile stocks in BE Market | 2.4% |
Stable Share Price: HYL's share price has been volatile over the past 3 months.
Volatility Over Time: HYL's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the topical treatment of external genital and perianal warts caused by certain types of the Human Papilloma Virus; and Sotalol IV, a drug used for atrial fibrillation. It also offers cardiovascular products under varying stages of development such as Aspirin IV, for acute coronary syndrome; Milrinone, for advanced heart failure; Dofetilide IV, for atrial fibrillation; Metolazone IV, congestive heart failure; HY-074, for acute coronary syndrome; and HY-075 for treating coronary heart disease.
Hyloris Pharmaceuticals SA Fundamentals Summary
| HYL fundamental statistics | |
|---|---|
| Market cap | €146.72m |
| Earnings (TTM) | -€15.38m |
| Revenue (TTM) | €4.21m |
34.8x
P/S Ratio-9.5x
P/E RatioIs HYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYL income statement (TTM) | |
|---|---|
| Revenue | €4.21m |
| Cost of Revenue | €93.00k |
| Gross Profit | €4.12m |
| Other Expenses | €19.50m |
| Earnings | -€15.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 97.79% |
| Net Profit Margin | -364.97% |
| Debt/Equity Ratio | 0% |
How did HYL perform over the long term?
See historical performance and comparison